Moderna and Merck Cancer Vaccine Succeeds in 1,000 Patients

A decade of research just delivered what scientists have chased for more than 100 years: a cancer vaccine that works.

Moderna and Merck announced on August 28, 2026, that their personalized mRNA vaccine successfully completed a late-stage trial with over 1,000 melanoma patients. When combined with immunotherapy, the vaccine prevented tumors from returning or spreading by teaching each patient's immune system to recognize their specific cancer mutations.

Moderna CEO Stéphane Bancel got the news on August 13 while celebrating a friend's birthday at a Lebanese restaurant. He compared it to the moment in 2020 when his company's COVID-19 vaccine succeeded, saying cancer eventually touches almost everyone.

The breakthrough came from combining three advances: mRNA technology, checkpoint inhibitor drugs, and affordable genetic sequencing. Previous cancer vaccine attempts failed because they only targeted one or two tumor mutations, but this vaccine targets 34 personalized mutations in each patient.

The vaccine works by carrying genetic instructions that direct the immune system toward a patient's specific cancer cell mutations. Doctors create it using a sample of each person's tumor, making every dose unique.

Melanoma was chosen for the trial because this skin cancer has many mutations and already responds well to immunotherapy drugs like Keytruda. Patients received the vaccine after surgery, giving their immune systems time to mount a defense before cancer could spread.

Robert Langer, a researcher involved in the project, explained that targeting dozens of mutations instead of just one or two dramatically increases the chances of success. Only one of those 34 targets needs to work for the treatment to help.

The Ripple Effect

The success opens doors beyond melanoma. Moderna and Merck are already testing the approach on lung, kidney, and pancreatic cancers to see if it works on tumors with fewer mutations.

For patients, approval could come as early as next year. The companies are preparing their data for FDA review after sharing results at an international oncology conference.

Tal Zaks, who worked on cancer vaccines since 1996, watched countless attempts fail over decades. The partnership between Moderna and Merck began in 2016, with Merck investing $450 million over six years in the technology.

After the announcement, Moderna's stock price jumped more than 130 percent from pandemic-era lows. Analysts predict the vaccine could generate over $1 billion in sales by 2030 and reach $3 billion by 2035.

Dean Li, who reviewed the research, said the combination of Keytruda unleashing immune system attack cells and the vaccine giving them 34 personalized targets creates a powerful one-two punch against cancer. With personalized treatment, those immune cells know exactly what to hunt.

The companies will now analyze detailed trial data to understand exactly why the vaccine worked and how to make it even more effective across different cancer types.